Rho GTPase-Activating Protein 35 rs1052667 Polymorphism and Osteosarcoma Risk and Prognosis

Table 3

The rs1052667 polymorphism of ARHGAP35 and osteosarcoma risk stratified by race (Han and minority), gender (female and male), and age (≤26 yrs and >26 yrs).

Variable	Genotype	Control		Case		OR (95% CI)^a	𝑃
		𝑛	%	𝑛	%
Race^b	rs1052667
Han	CC	218	78.1	82	51.6	1
	CT/TT	61	21.9	77	48.4	3.40 (2.22–5.19)	1.61×10^−8
Minority	CC	123	82.6	51	58.0	1
	CT/TT	26	17.4	37	42.0	3.39 (1.86–6.18)	6.67×10^−5
Gender^c	rs1052667
Female	CC	129	79.1	49	52.7	1
	CT/TT	34	20.9	44	47.3	3.42 (1.96–5.98)	1.53×10^−5
Male	CC	212	80.0	84	54.5	1
	CT/TT	53	20.0	70	45.5	3.29 (2.12–5.12)	1.08×10^−7
Age^d	rs1052667
≤26	CC	214	77.0	80	49.7	1
	CT/TT	64	23.0	81	50.3	3.40 (2.23–5.17)	1.11×10^−8
>26	CC	127	84.7	53	61.6	1
	CT/TT	23	15.3	33	38.4	3.35 (1.79–6.25)	1.50×10^−4

aOR conditional on matched set.
^bLikelihood ratio test for interaction of the stratified variable (Han and Minority) and rs1052667 genotype was calculated as test for the heterogeneity of ORs across strata (interact term OR = 1.02, P _interaction= 0.957).
^cLikelihood ratio test for interaction of the stratified variable (male and female) and rs1052667 genotype was calculated as test for the heterogeneity of ORs across strata (interact term OR = 0.99, P _interaction= 0.983).
^dLikelihood ratio test for interaction of the stratified variable (age: ≤26 yrs and >26 yrs) and rs1052667 genotype was calculated as test for the heterogeneity of ORs across strata (interact term OR = 1.01, P _interaction= 0.982).